# Phenotypic Spectrum in Three Romanian Patients with 8q23–q24 Deletions

**Authors:** Alexandru Caramizaru, Ioana Streata, Andrei Pirvu, Simona Sosoi, Andreea Dumitrescu, Mihai Cucu, Georgiana-Cristiana Camen, Daniela Vasile, Elena Braha, Anca-Lelia Riza, Amelia Dobrescu, Florin Burada

PMC · DOI: 10.3390/ijms27031249 · International Journal of Molecular Sciences · 2026-01-27

## TL;DR

This paper describes three Romanian patients with deletions in the 8q23–q24 region and expands the known clinical and genetic features of TRPS II.

## Contribution

The study adds new clinical and genetic data from three unrelated patients with 8q23–q24 deletions, expanding the understanding of TRPS II and genotype–phenotype correlations.

## Key findings

- The deletions in the three patients vary in size, genomic coordinates, and gene content.
- One deletion does not include TRPS1, and another excludes both TRPS1 and RAD21.
- The findings support the heterogeneity of clinical features associated with 8q23–q24 deletions.

## Abstract

Trichorhinophalangeal syndrome type II (TRPS II) is a rare disease caused by a contiguous gene deletion in the 8q23.3–q24.11 region. Three genes (TRPS1, RAD21, and EXT1) are considered responsible for the most common clinical features, which include facial dysmorphism, ectodermal and skeletal anomalies, osteochondromas, and cognitive impairment. To date, seven patients with 8q23–q24 deletions not involving TRPS1 have been reported, with phenotypes overlapping TRPS II. In this paper, we present clinical and genetic aspects from three non-related patients with 8q23–q24 deletions, and we review the available testing strategies for such patients and their families. The deletions harbored by these patients have been identified through microarray, with two of them also undergoing initial MLPA evaluation. The observed clinical and genetic features are heterogeneous, and generally in keeping with known associations between the three main genes from the deleted region and the clinical manifestations of TRPS II. Particularly, the deleted regions vary substantially in size, genomic coordinates, and gene content, with one not including TRPS1, and another, with a more distal loss, not including either TRPS1 nor RAD21. By describing three new patients, we hope to enlarge the genetic and clinical landscape of TRPS II and 8q23–q24 deletions, and help identify further genotype–phenotype correlations.

## Linked entities

- **Genes:** TRPS1 (transcriptional repressor GATA binding 1) [NCBI Gene 7227], RAD21 (RAD21 cohesin complex component) [NCBI Gene 5885], EXT1 (exostosin glycosyltransferase 1) [NCBI Gene 2131]
- **Diseases:** Trichorhinophalangeal syndrome type II (MONDO:0007874)

## Full-text entities

- **Genes:** EXT1 (exostosin glycosyltransferase 1) [NCBI Gene 2131] {aka EXT, LGCR, LGS, TRPS2, TTV}, RAD21 (RAD21 cohesin complex component) [NCBI Gene 5885] {aka CDLS4, HR21, HRAD21, MCD1, MGS, NXP1}, TRPS1 (transcriptional repressor GATA binding 1) [NCBI Gene 7227] {aka GC79, LGCR}
- **Diseases:** osteochondromas (MESH:D015831), cognitive impairment (MESH:D003072), TRPS II (MESH:D015826), facial dysmorphism (MESH:C565579), ectodermal and skeletal anomalies (MESH:C537408)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12898156/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12898156/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC12898156/full.md

---
Source: https://tomesphere.com/paper/PMC12898156